NASDAQ:CYAD Celyad Oncology - CYAD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celyad Oncology SA Please log in to your account or sign up in order to add this asset to your watchlist. $1.35 0.00 (0.00%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.32▼$1.4950-Day Range$0.49▼$2.3752-Week Range$0.46▼$3.63Volume78,929 shsAverage Volume4.53 million shsMarket Capitalization$30.50 millionP/E RatioN/ADividend YieldN/APrice Target$2.78 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Celyad Oncology (NASDAQ:CYAD) StockCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Read More Receive CYAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CYAD Stock News HeadlinesJanuary 18, 2023 | ca.finance.yahoo.comCelyad Oncology SA (CYAD)January 17, 2023 | benzinga.comThinking about buying stock in Celyad Oncology, Calyxt, IQIYI, Vinco Ventures, or Carvana?January 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 29, 2022 | finance.yahoo.comCelyad Oncology Completely Shifts To Preclinical Stage, Pulls Plug On Only Human Trial AssetDecember 21, 2022 | tmcnet.comCelyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harnessDecember 21, 2022 | markets.businessinsider.comCelyad Oncology To Discontinue CYAD-211 Clinical Program In Multiple MyelomaDecember 21, 2022 | seekingalpha.comCelyad stock slumps 25% as blood cancer drug CYAD-211 gets axed in strategic reviewDecember 21, 2022 | finance.yahoo.comCelyad Oncology Provides an Update on Its Strategic Business Model, Continuing to Focus on Opportunities to Fully Harness the True Potential of Its Proprietary Technology Platforms and Intellectual PropertyJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 11, 2022 | reuters.comCelyad Oncology SANovember 10, 2022 | finance.yahoo.comCelyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business HighlightsOctober 12, 2022 | finance.yahoo.comCelyad Oncology Provides Strategic UpdateSeptember 20, 2022 | finance.yahoo.comCellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations TransactionAugust 5, 2022 | seekingalpha.comCelyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call TranscriptAugust 1, 2022 | nasdaq.comCelyad: FDA Lifts Clinical Hold On CYAD-101-002 Phase 1b TrialAugust 1, 2022 | markets.businessinsider.comDaily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer TrialAugust 1, 2022 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b TrialAugust 1, 2022 | finance.yahoo.comCelyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b TrialJuly 28, 2022 | finance.yahoo.comCelyad Oncology to Announce First Half 2022 Financial Results and Host Conference CallJuly 19, 2022 | seekingalpha.comCelyad: Probably Still Top-Notch In OncologyJune 24, 2022 | finance.yahoo.comCelyad Oncology Announces Leadership UpdatesMay 25, 2022 | finance.yahoo.comCelyad SA (CYAD) Upgraded to Buy: Here's What You Should KnowMay 17, 2022 | finance.yahoo.comCelyad Oncology to Present at the H.C. Wainwright Global Investment ConferenceMay 5, 2022 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business HighlightsMay 5, 2022 | seekingalpha.comCelyad Oncology reports Q1 resultsMay 5, 2022 | finance.yahoo.comCORRECTING AND REPLACING: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business HighlightsMay 5, 2022 | finance.yahoo.comCORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business HighlightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CYAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CYAD Company Calendar Today1/31/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYAD CUSIPN/A CIK1637890 Webwww.celyad.com Phone(210) 039-4100Fax321-039-4141Employees95Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.78 High Stock Price Forecast$2.78 Low Stock Price Forecast$2.78 Forecasted Upside/Downside+105.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio1.71 Quick RatioN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales3,049.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.29 per share Price / Book0.59Miscellaneous Outstanding Shares22,590,000Free Float22,382,000Market Cap$30.50 million OptionableNot Optionable Beta1.38 Key ExecutivesMichel E. LussierChief Executive Officer & Executive DirectorDavid GeorgesVice President-Finance & AdministrationEytan BremanDirector-Research & DevelopmentFrederic LehmannVP-Clinical Development & Medical AffairsDavid GilhamChief Scientific OfficerKey CompetitorsAkari TherapeuticsNASDAQ:AKTXCumberland PharmaceuticalsNASDAQ:CPIXAcer TherapeuticsNASDAQ:ACERDiaMedica TherapeuticsNASDAQ:DMACCorvus PharmaceuticalsNASDAQ:CRVSView All Competitors CYAD Stock - Frequently Asked Questions Should I buy or sell Celyad Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CYAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYAD, but not buy additional shares or sell existing shares. View CYAD analyst ratings or view top-rated stocks. What is Celyad Oncology's stock price forecast for 2023? 2 analysts have issued 1 year price objectives for Celyad Oncology's shares. Their CYAD share price forecasts range from $2.78 to $2.78. On average, they expect the company's share price to reach $2.78 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for CYAD or view top-rated stocks among Wall Street analysts. How have CYAD shares performed in 2023? Celyad Oncology's stock was trading at $0.4929 at the beginning of the year. Since then, CYAD shares have increased by 194.2% and is now trading at $1.45. View the best growth stocks for 2023 here. When is Celyad Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our CYAD earnings forecast. What other stocks do shareholders of Celyad Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX). When did Celyad Oncology IPO? (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. What is Celyad Oncology's stock symbol? Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD." How do I buy shares of Celyad Oncology? Shares of CYAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celyad Oncology's stock price today? One share of CYAD stock can currently be purchased for approximately $1.45. How much money does Celyad Oncology make? Celyad Oncology (NASDAQ:CYAD) has a market capitalization of $32.76 million and generates $10,000.00 in revenue each year. How can I contact Celyad Oncology? Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The official website for the company is www.celyad.com. The company can be reached via phone at (210) 039-4100 or via fax at 321-039-4141. This page (NASDAQ:CYAD) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.